KYMERA Trademark

Trademark Overview

On Monday, November 16, 2020, a trademark application was filed for KYMERA with the United States Patent and Trademark Office. The USPTO has given the KYMERA trademark a serial number of 90320564. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, December 2, 2024. This trademark is owned by Kymera Therapeutics, Inc.. The KYMERA trademark is filed in the Pharmaceutical Products category with the following description:

House mark for pharmaceutical and medical preparations for the treatment of oncology, autoimmune, immune-oncology and other related diseases; House mark for pharmaceutical and medical therapeutics for the treatment of oncology, autoimmune, immune-oncology and other related diseases; House mark for diagnostic reagents for the treatment of oncology, autoimmune, immune-oncology and other related diseases

General Information

Serial Number90320564
Word MarkKYMERA
Filing DateMonday, November 16, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, December 2, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, August 31, 2021

Trademark Statements

Description of MarkThe mark consists of several geometric designs that form the basic elements of an animal face, with the wording "KYMERA" in capital stylized letters appearing to the right of the design and the "K" forming the base of the face.
Goods and ServicesHouse mark for pharmaceutical and medical preparations for the treatment of oncology, autoimmune, immune-oncology and other related diseases; House mark for pharmaceutical and medical therapeutics for the treatment of oncology, autoimmune, immune-oncology and other related diseases; House mark for diagnostic reagents for the treatment of oncology, autoimmune, immune-oncology and other related diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, January 14, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameKymera Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressWatertown, MA 02472
Party NameKymera Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWatertown, MA 02472

Trademark Events

Event DateEvent Description
Thursday, November 19, 2020NEW APPLICATION ENTERED
Thursday, January 14, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, January 15, 2021NOTICE OF DESIGN SEARCH CODE E-MAILED
Thursday, April 22, 2021ASSIGNED TO EXAMINER
Friday, April 23, 2021PREVIOUS ALLOWANCE COUNT WITHDRAWN
Friday, April 23, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, April 23, 2021NON-FINAL ACTION WRITTEN
Friday, April 23, 2021NON-FINAL ACTION E-MAILED
Friday, April 23, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, May 5, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, July 1, 2021ASSIGNED TO LIE
Friday, July 2, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, July 2, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, July 27, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, August 11, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 31, 2021PUBLISHED FOR OPPOSITION
Tuesday, August 31, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 26, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, April 25, 2022SOU TEAS EXTENSION RECEIVED
Monday, April 25, 2022SOU EXTENSION 1 FILED
Monday, April 25, 2022SOU EXTENSION 1 GRANTED
Wednesday, April 27, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, October 19, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, October 19, 2022SOU EXTENSION 2 FILED
Wednesday, October 19, 2022SOU EXTENSION 2 GRANTED
Friday, October 21, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, April 18, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, April 18, 2023SOU EXTENSION 3 FILED
Tuesday, April 18, 2023SOU EXTENSION 3 GRANTED
Thursday, April 20, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 17, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, October 17, 2023SOU EXTENSION 4 FILED
Tuesday, October 17, 2023SOU EXTENSION 4 GRANTED
Thursday, October 19, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, April 26, 2024DIVISIONAL REQUEST RECEIVED
Friday, April 26, 2024SOU EXTENSION 5 FILED
Friday, April 26, 2024SOU TEAS EXTENSION RECEIVED
Friday, April 26, 2024TEAS REQUEST TO DIVIDE RECEIVED
Friday, May 24, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, June 12, 2024ITU OFFICE ACTION ISSUED FOR DIVISIONAL REQUEST
Wednesday, June 26, 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, June 26, 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, June 26, 2024TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Wednesday, June 26, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, June 26, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, June 26, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, June 26, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, July 10, 2024SOU EXTENSION 5 GRANTED
Wednesday, July 10, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 17, 2024DIVISIONAL PROCESSING COMPLETE
Wednesday, July 17, 2024CORRECTED NOA E-MAILED
Monday, December 2, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, December 2, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, December 2, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, December 2, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED

Related Keywords

kymera oncology house immune related diseases other autoimmune mark treatment pharmaceutical